Osugacestat

Drug Overview

Osugacestat (also known by its developmental codes AL101, BMS-906024, and BM-0018) is an investigational, small-molecule gamma-secretase (GS) inhibitor and a potent pan-Notch inhibitor. It is specifically designed to block the activation of Notch receptors, which are critical drivers of cellular proliferation, differentiation, and survival in a variety of aggressive malignancies.

In the clinical landscape of March 2026, osugacestat is recognized as a leading precision medicine candidate for the treatment of adenoid cystic carcinoma (ACC), a rare and often lethal secretory gland cancer. Approximately 20% of ACC patients harbor activating mutations in the NOTCH genes (specifically NOTCH1), which lead to an aggressive disease course and resistance to traditional chemotherapy.

By inhibiting the gamma-secretase enzyme complex, osugacestat prevents the “cleavage” and subsequent activation of the Notch signaling pathway, effectively turning off the genetic switches that allow the cancer to grow and spread. Developed by Ayala Pharmaceuticals (originally discovered by Bristol Myers Squibb), osugacestat represents a targeted approach to treating tumors that have become “addicted” to Notch signaling.

• Generic Name: Osugacestat.
• Code Names: AL101, BMS-906024, BM-0018.
• Drug Class: Gamma-secretase Inhibitor (GSI); Pan-Notch Inhibitor.
• Mechanism: Inhibition of the gamma-secretase-mediated cleavage of Notch receptors (Notch 1, 2, 3, and 4).
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational. As of March 2026, osugacestat is not FDA-approved. It has been granted Orphan Drug Designation for several indications and is currently being evaluated in late-stage clinical trials.

What Is It and How Does It Work? (Mechanism of Action)

Osugacestat works by interrupting the “Notch signaling cascade,” a communication pathway that cancer cells exploit to maintain their malignant properties.

1. The Role of Gamma-Secretase

Notch receptors are proteins that sit on the cell surface. When a signal binds to the outside of the receptor, the gamma-secretase enzyme complex acts like a pair of “molecular scissors” that cuts the internal portion of the receptor, known as the Notch Intracellular Domain (NICD).

• Release of NICD: Once cut, the NICD travels into the cell’s nucleus.
• Gene Activation: Inside the nucleus, it binds to DNA and activates a suite of genes that promote rapid cell division and block the cell from dying.

2. Selective Inhibition

Osugacestat binds to and inhibits the gamma-secretase complex, preventing it from cutting the Notch receptors.

• Pan-Notch Blockade: It inhibits all four Notch receptors (Notch 1-4), providing a comprehensive shutdown of the pathway.
• Tumor Suppression: Without the NICD in the nucleus, the pro-growth genetic program is halted, leading to tumor cell cycle arrest and apoptosis (programmed cell death).

3. Targeting “Notch-Addicted” Cancers

While many cancers can involve some degree of Notch signaling, osugacestat is most effective in tumors where the pathway is “constitutively active” due to genetic mutations. In these cases, the “molecular scissors” are working non-stop, and osugacestat acts as a precise brake on this runaway growth.

Clinical Indications and Research Status (2026)

As of early 2026, osugacestat is the focus of several clinical programs targeting “Notch-driven” rare tumors:

• Adenoid Cystic Carcinoma (ACC): The most advanced area of research. The Phase 2 ACCURACY trial is evaluating osugacestat in patients with recurrent or metastatic ACC who harbor NOTCH1, 2, 3, or 4 mutations.
• T-cell Acute Lymphoblastic Leukemia (T-ALL): Evaluated in earlier-phase studies due to the high frequency of NOTCH1 mutations in this type of leukemia.
• Triple-Negative Breast Cancer (TNBC): Investigated as part of combination therapies to target “Notch-positive” cancer stem cells, which are often the source of treatment resistance and relapse.
• Solid Tumors with Notch Mutations: Current 2026 research is exploring a “tissue-agnostic” approach, testing osugacestat in any advanced solid tumor—such as colorectal or lung cancer—that tests positive for an activating Notch mutation via genomic sequencing.

Dosage and Administration Protocols

As an investigational drug, osugacestat dosing is strictly managed within clinical trial protocols (such as the AL101-ACC-201 study).

Clinical Efficacy and Research Results (2024–2026)

Recent data from the Phase 2 clinical programs have provided significant insights:

• Tumor Shrinkage: In patients with Notch-mutated ACC, osugacestat has demonstrated an Objective Response Rate (ORR) of approximately 15-20%, which is a significant clinical achievement in a disease that typically does not respond to conventional chemotherapy.
• Disease Control: Over 60% of patients achieved “stable disease,” with many maintaining this status for more than six months.
• Biomarker Selection: Research confirms that patients without Notch mutations derive very little benefit from the drug, establishing osugacestat as a truly biomarker-driven precision therapy.

Safety Profile and Side Effects

The side effects of osugacestat are primarily related to its inhibition of Notch signaling in healthy tissues, particularly the gut and the skin.

Common Side Effects (>25%):

• Diarrhea: The most frequent side effect, as Notch signaling is essential for the healthy turnover of the intestinal lining.
• Fatigue: General systemic tiredness and weakness.
• Nausea: Managed with standard anti-nausea medications.
• Skin Changes: Rash or dry skin (xerosis).

Serious Risks:

• Gastrointestinal Toxicity: Severe (Grade 3) diarrhea may occur, requiring dose delays or treatment with aggressive anti-diarrheal medications.
• Hypophosphatemia: Low levels of phosphorus in the blood, which may require supplementation.
• Secondary Cancers: Some gamma-secretase inhibitors have been associated with a potential risk of non-melanoma skin cancers (like squamous cell carcinoma) due to the role of Notch in skin health; regular skin exams are mandatory.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, osugacestat is used to study the “Cancer Stem Cell Niche.” Researchers are investigating how blocking Notch signaling can “deplete” the population of cancer stem cells that are responsible for tumor recurrence after surgery or radiation. In 2026, there is also intense focus on “Immune-Oncology Combinations.” Scientists are conducting early-phase trials to see if osugacestat can “re-program” the tumor environment to make it more receptive to checkpoint inhibitors (like pembrolizumab).

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• Genomic Sequencing: Mandatory Next-Generation Sequencing (NGS) of the tumor to confirm the presence of an activating NOTCH mutation.
• Baseline GI Health: Detailed assessment of baseline bowel habits and nutritional status.

“Do’s and Don’ts” List:

• DO report any “increase in bowel movements” immediately; early management of diarrhea with loperamide is critical to staying on the treatment.
• DO keep all appointments for weekly infusions; the drug’s half-life requires consistent dosing to maintain therapeutic levels.
• DON’T ignore new skin growths or sores; regular skin exams by a dermatologist are recommended due to the potential risk of non-melanoma skin lesions.
• DON’T start any new medications without consulting your study team, as certain drugs can interfere with the way the body processes osugacestat.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Osugacestat (AL101) is an investigational agent and is not approved by the U.S. FDA for commercial use. Access is restricted exclusively to registered clinical trials. Always consult with a qualified oncologist or principal investigator regarding your specific diagnosis and eligibility for research participation.